ADA Scientific Sessions 2026 Abstract

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study

By Wei Hu, Yijun Du, Qian Zhang, Yuanyuan Zhang

Trial in peopleInterventions

The paper

Wei Hu, Yijun Du, Qian Zhang, Yuanyuan Zhang

Hefei

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1721-P

doi.org/10.2337/db26-1721-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes